Stockscreener 앱 받기
8.15
0.00%
0.00
시간 외 거래:
8.15
Immunitybio Inc 주식(IBRX)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ImmunityBio stock (US45258J1025): Class action deadline nears amid FDA scrutiny - AD HOC NEWS
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - PR Newswire
IBRX stock eyes best week since February: Founder highlights new Anktiva-NK cell therapy study - MSN
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, - GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
IBRX stock enters heavy catalyst phase: Traders brace for key Anktiva decision amid Trump’s FDA turmoil - MSN
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit S - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Morningstar
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is 'almost there' - MSN
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
IBRX stock can't shake FDA delay overhang: Founder touts Saudi and Greece progress with Anktiva as bright spots - MSN
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered LossesContact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline - The Globe and Mail
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Loss - The National Law Review
IBRX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - ChartMill
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results - simplywall.st
ImmunityBio, Inc. (NASDAQ:IBRX) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
Immunitybio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IBRX Stock Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
IBRX Stock Can't Shake FDA Delay Overhang: Founder Touts Saudi And Greece Progress With Anktiva As Bright Spots - Stocktwits
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ImmunityBio, Inc. (NASDAQ: IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
Press releases provided by CNW - Techaeris
INVESTOR DEADLINE REMINDER: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Globe and Mail
Securities Class Action Deadline Against ImmunityBio, Inc. (NASDAQ: IBRX)Contact Kaplan Fox Before May 26, 2026 - The National Law Review
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
IBRX stock jumps after-hours: Bulls cheer 'unstoppable' global expansion amid US regulatory heat for Anktiva - MSN
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins ... - Caledonian Record
IBRX Investor Alert – ImmunityBio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action - GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
IBRX Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) - PR Newswire
IMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026 - The Globe and Mail
IBRX Lawsuit Alleges Company Allegedly Violated Drug - GlobeNewswire
FinancialContentIMMUNITYBIO CLASS ACTION DEADLINE: Kaplan Fox Encourages ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on May 26, 2026 - FinancialContent
Piper Sandler Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
0.96%
0.26%
자본화:
|
볼륨(24시간):